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Global Mortality and Morbidity in Heart Failure) trial, treatment with the angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) was associated with a 20% reduction in the primary composite endpoint of cardiovascular death or HF hospitalization compared with enalapril (6). Moreover, LCZ696 reduced both the time to first hospitalization for HF and the cumulative burden of HF hospitalizations during the course of the trial (7) . In this analysis, we sought to further assess the effect of LCZ696 on the rates of all-cause 30-day readmission after HF hospitalization. Those in which patients died before discharge, were admitted and discharged on the same day, or for which discharge dates were unavailable were excluded. Discharges for which readmission status was not able to be determined because of study discontinuation were omitted from the analysis. When conflicting admission and/or discharge dates were encountered, we used the widest hospitalization interval from among the conflicting dates (i.e., the earliest admission date and the latest discharge date). In keeping with the Medicare methodology, a readmission was defined as inpatient admission to an acute care facility for any cause within 30-days from the date of discharge of an index HF hospitalization. The results of sensitivity analyses are reported in Shown are the proportion of investigator-reported HF hospitalizations associated with readmissions for any cause or for heart failure at 30 days and 60 days following discharge. LCZ696 ¼ sacubitril/valsartan.
In this analysis, we noted a 26% lower rate of 30-day readmission for any cause among patients allocated to LCZ696 and a 38% lower rate of 30-day readmission for HF. These differences persisted at 60 days following hospital discharge and were robust in analyses restricted to CEC-adjudicated HF hospitalizations, patients enrolled in the United States, and the subset of Medicare-eligible subjects >65 years of age.
These data suggest that LCZ696 is likely to be more effective than enalapril in reducing the risk of early readmission after HF hospitalization.
Recurrent hospitalizations are a primary driver of the burgeoning costs associated with HF care (3) and are a potent marker of risk for subsequent mortality (9, 10) . Although patients discharged with HF are at risk for readmission well beyond 30 days, the early post-discharge interval is known to be a particularly vulnerable period (11, 12) . In the United States, TRANSLATIONAL OUTLOOK: Future studies should seek to clarify the mechanism by which composite angiotensin receptorneprilysin inhibition exerts benefit beyond the acute hospital phase of treatment compared with angiotensin-converting enzyme inhibition alone in patients with progressive heart failure and reduced ejection fraction. Influence of LCZ696 on 30-Day Readmission
